Brind.

Alkermes Reports 31% Proprietary Product Sales Growth in Q3 2026

1 report, 1 independent Updated Tue 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Blair Jackson was appointed as the Chief Executive Officer of Alkermes. The company reported third-quarter 2026 results, which showed 31% year-over-year growth in proprietary product sales. Total revenue for the quarter ended September 30 was $480.1 million, with proprietary product net sales reaching $417.3 million.

From dailypolitical.com

Why it matters

Some supportBrind's analysis of the reports

Alkermes maintained its full-year revenue guidance for its four proprietary brands. Jackson stated that the company aims to advance its pipeline while maintaining commercial performance. The growth in sales was attributed to contributions from the company’s addiction, psychiatry, and sleep-medicine products.

From dailypolitical.com

Who's involved

  • AlkermesCompany reporting Q3 results and appointing a new CEO.
  • JacksonNew Chief Executive Officer of Alkermes.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • Eli Lilly and CompanySpeculative

    Could face increased competitive pressure in the narcolepsy segment due to Alkermes's proprietary sales growth.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped